Cyrano Therapeutics is a clinical-stage regenerative medicine company based in Delray Beach, FL, focused on developing therapies for patients with loss of smell and taste. Its lead program is CYR-064, an intranasal theophylline spray intended to treat post-viral hyposmia. The company is conducting FLAVOR, a Phase 2, randomized, double-blind, placebo-controlled, multi-dose, multi-site trial enrolling 150 subjects at up to 15 U.S. sites. Cyrano intends to use recent financing to advance the FLAVOR trial. The company is led by President and CEO Rick Geoffrion. It is positioned as a clinical-stage developer advancing a first-of-its-kind treatment for long-term smell loss due to viral infection. Cyrano Therapeutics is a clinical-stage regenerative medicine company developing a novel intranasal therapy to restore smell and flavor. Its lead product, CYR-064, is in development to treat chronic smell and flavor loss and the company plans to complete a Phase 2 clinical trial in the U.S. and Europe. The company raised $12.8 million in a Series A to fund completion of that Phase 2 trial. The financing was led by Remiges Ventures and Lumira Ventures, and as part of the round Taka Koda of Remiges and Gerry Brunk of Lumira joined Cyrano's board. Cyrano intends to include patients with COVID-19-related smell loss as well as those whose dysfunction stems from other viral infections or causes such as influenza, allergic rhinitis and traumatic brain injury. The company was co-founded by CEO Rick Geoffrion and Robert Henkin, PhD, director of The Taste and Smell Clinic in Washington, D.C., after Geoffrion experienced long-term smell loss himself.

Total raised

$22M

Funding rounds

2

Latest round

Series B

Latest activity

Jan 2024